Rapport Therapeutics, Inc. Common Stock
Financials
Valuation Metrics
Rapport Therapeutics, Inc. Common Stock's Market Cap is $1.20B. At end of 2025 it was $1.43B. Ranked #2372 of 3,115 in US market (top 76%), #959 of 1,472 on NASDAQ (top 65%), #175 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.20B | US#2,372/3,115 Sec#175/265 |
| Revenue | $20M | US#2,790/3,115 Sec#161/265 |
| Net Income | $-137M | US—/3,115 Sec—/265 |
| Total Assets | $459M | US#2,796/3,115 Sec#172/265 |
| Net Assets | $423M | US#2,327/3,115 Sec#127/265 |
| Employees | 84 | US#2,646/3,115 Sec#187/265 |
| Value | ||
| P/B | 2.83x | US#1,570/3,115 Sec#79/265 |
| P/S | 59.93x | US#2,924/3,115 Sec#168/265 |
| FCF Yield | -8.11% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -32.43% | US#2,579/3,115 Sec#119/265 |
| ROA | -29.88% | US#2,876/3,115 Sec#155/265 |
| Op. Margin | -767.58% | US#2,798/3,115 Sec#161/265 |
| Financial Health | ||
| Debt Ratio | 8.53% | US#84/3,115 Sec#40/265 |
| Total Debt | $10M | US#2,826/3,115 Sec#197/265 |
| FCF | $-97M | US#2,627/3,115 Sec#141/265 |
| Cash | $64M | US#2,465/3,115 Sec#209/265 |
| Current Ratio | 15.72x | US#159/3,115 Sec#46/265 |
| Performance | ||
| 1Y Return | -13.38% | US#2,411/3,115 Sec#191/265 |
| 1M Return | -22.10% | US#3,045/3,115 Sec#253/265 |
| From 52W High | -52.65% | US#2,829/3,115 Sec#222/265 |
| 1Y MDD | -57.14% | US#2,663/3,115 Sec#196/265 |
| Trading | ||
| Volume | 1,137,516 shares | US#308/3,115 Sec#22/265 |
| Trading Value | $29M | US#714/3,115 Sec#35/265 |
| Per Share | ||
| EPS | $-2.87 | US—/3,115 Sec—/265 |
| BPS | $8.84 | US#1,913/3,115 Sec#76/265 |
Company Info
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.